Mode
Text Size
Log in / Sign up

Naltrexone-Bupropion Aids Weight Loss in Overweight Adults With DepressionA New Weight Loss Drug Helps Depression Too

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider NB-ER for weight loss in patients with overweight/obesity and mild to moderate depression, but depression improvements are similar to placebo.

This pooled analysis of 4 double-blind, placebo-controlled trials evaluated the fixed-dose combination of naltrexone and bupropion (NB-ER) in 511 individuals with overweight or obesity and mild to moderate depressive symptoms. Participants received NB-ER or placebo for 56 weeks. The primary outcomes were percent weight loss and changes in depression.

NB-ER resulted in significantly greater weight loss than placebo (5.7% ± 0.6% vs. 2.7% ± 0.8%, p = 0.003). Depression scores improved in both groups, with no significant difference between NB-ER (-7.1 ± 0.4) and placebo (-6.7 ± 0.5). Psychiatric adverse events occurred in 27.5% of NB-ER users and 22.1% of placebo users, a non-significant difference. Rates of depressive symptom increases (9.5% vs. 8.8%) and suicidal ideation (1.8% vs. 2.0%) were also similar between groups.

Safety signals did not differ between NB-ER and placebo. Serious adverse events and discontinuation rates were not reported. The analysis was limited by its pooled design and lack of reporting on certain safety details.

Clinically, NB-ER appears safe and effective for weight loss in patients with mild to moderate depression, though depression outcomes were not superior to placebo. Clinicians should monitor psychiatric symptoms as per standard practice.

A New Weight Loss Drug Helps Depression Too

The Struggle Is Real For Many

Imagine trying to lose weight while feeling down every day. It feels like climbing a hill with a heavy backpack. Many people face this exact struggle. They want to feel better physically and mentally. But current options often force a choice between losing weight and feeling happy.

Doctors usually treat these issues separately. You might take one pill for your weight and another for your mood. Sometimes the weight loss drugs make you feel anxious or depressed. Other mood medicines can cause weight gain. Patients often feel stuck in this impossible situation.

Depression is very common among people trying to lose weight. About one in five adults in the United States deals with this condition. When someone feels sad or hopeless, their body fights against change. They crave comfort foods and lack the energy to move. This creates a vicious cycle that is hard to break.

Current treatments do not address both problems at once. Patients often stop taking their weight loss medicine because it makes them feel worse. Or they stop their mental health treatment because they fear weight gain. This new research changes that dynamic. It offers a single solution for two big problems.

The Old Way Vs The New Way

For years, doctors treated obesity and depression as separate enemies. They assumed that losing weight would automatically fix mood issues. Or they assumed that fixing mood would make weight loss easier. But the data did not always support these beliefs.

But here is the twist. This new study shows that you can tackle both issues together. The drug used in the trial does two things at once. It blocks signals that make you crave food. It also helps your brain feel more balanced and calm. This combination approach is different from the old way of picking and choosing treatments.

How It Works In The Body

Think of your brain like a busy factory floor. Some workers send signals to store fat and crave sugar. These signals get too loud when you are stressed or sad. The new drug acts like a manager who silences these loud workers. It stops the fat storage signals without shutting down the whole factory.

The drug also acts like a thermostat for your mood. It helps regulate the chemicals that control feelings. When these chemicals are balanced, you feel less sad and more hopeful. This hope gives you the motivation to eat well and move more. It is like turning on a light in a dark room. You can finally see the path forward.

Researchers looked at data from four different trials. They studied 511 people who had extra weight and felt down. These people took the new drug or a fake pill for 56 weeks. The results were clear and meaningful for patients everywhere.

People on the new drug lost 5.7 percent of their starting weight. Those on the fake pill lost only 2.7 percent. That is a big difference in real life. It means more people can reach their weight goals without giving up. Their depression scores also improved significantly. They felt better without needing extra medicine.

But There Is A Catch

This does not mean everyone will see these exact results.

The study had some limits that readers should know about. The group was small compared to the millions of people who need help. Also, the drug only worked for people with mild to moderate depression. Those with severe depression might need different care. The study also took place in controlled settings. Real life can be messier than a research trial.

If you struggle with weight and mood, talk to your doctor about this option. It is not a magic cure. It is a tool that might help you build a better life. You should discuss your full medical history first. Some people cannot take certain medicines due to other health issues. Your doctor will know if this fits your situation.

More research is coming soon. Scientists will test this drug in larger groups of people. They will also look at long term effects over many years. Approval processes take time for new medicines. Patients should be patient while waiting for official guidelines. The goal is to help more people live healthier lives.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up12.9 mo
PublishedMay 2026
View Original Abstract ↓
OBJECTIVE: The present study examined the safety and efficacy of the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) in individuals with overweight/obesity and mild to moderate symptoms of depression. METHODS: Data were pooled from four double-blind, placebo-controlled trials. Participants with baseline Inventory of Depressive Symptomatology-Self-Report scores ≥ 14 suggestive of mild or greater depressive symptoms were included (N = 511). Primary outcomes were 56-week percent weight loss and changes in depression, as well as safety data for psychiatric adverse events (PAEs), depressive symptom increases, and suicidal ideation. Multiple imputation was applied, and outcomes were compared in the intention-to-treat population. RESULTS: In participants with symptoms of depression, 56-week weight loss was significantly greater with NB-ER (5.7% ± 0.6%) than with placebo (2.7% ± 0.8%; p = 0.003). Participants experienced clinically meaningful improvements in depression of -7.1 ± 0.4 with NB-ER and -6.7 ± 0.5 with placebo, with no significant differences between the groups. NB-ER and placebo did not differ in safety signals including PAE occurrence (27.5% NB-ER vs. 22.1% placebo), depressive symptom increases (9.5% NB-ER vs. 8.8% placebo), or suicidal ideation (1.8% NB-ER vs. 2.0% placebo). CONCLUSIONS: NB-ER appears to be both safe and effective for weight loss when offered to patients with mild to moderate symptoms of depression.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.